Autonomix granted U.S patent on platform enabling precision therapies

Autonomix (AMIX) Medical announced the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,369,852, titled, “Controlled and Precise Treatment of Cardiac Tissues.” The newly issued ‘852 patent covers systems, devices, and methods that sense autonomic/cardiac signals, map targets, and then deliver therapy with closed-loop feedback to precisely treat cardiac tissues by performing feedback-driven neuromodulation, denervation, and/or ablation of tissues. “We are pleased to further reinforce our intellectual property around our technology. The autonomic nervous system plays a major role in regulating and maintaining normal cardiac activity. Cardiac disease is often treated by sympathetic beta-receptor blockade, which affects all cells and organs of the body and often leads to unwanted and intolerable side effects. Our breakthrough technology has the potential to provide precision nerve-targeted therapies that could transform treatment in high-growth areas of cardiology, including renal denervation for hypertension, arrhythmia management, heart failure, and refractory angina, offering new solutions with fewer complications,” commented Brad Hauser, CEO of Autonomix.